Hongli Group Inc. announced a leadership change with Michael W. Zhang appointed as Chairman of the Board, succeeding Jie Liu who remains CEO. Zhang brings strong expertise in finance and corporate governance and aims to guide the company’s diversification from steel manufacturing into clean energy and solid-state lithium battery technologies. This leadership transition highlights Hongli’s strategic move to expand beyond its traditional cold roll-formed steel profile business and create long-term shareholder value.
Hongli Group Inc. announced a new chairman appointment. For readers following the Basic Materials sector, here is Pluang's market snapshot as of Oct 06, 2026 03:02 WIB: Of 38 priced US stocks, 20 rose and 18 fell. Notable movers include VALE at USD 13.75 (+2.23%), DOW at USD 28.52 (+1.95%), and WPM at USD 136.00 (+1.93%).
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...
